Preparation and in vitro analysis of human serum albumin nanoparticles loaded with anthracycline derivatives

Kotaro Kimura, Keishi Yamasaki, Hideaki Nakamura, Mamoru Haratake, Kazuaki Taguchi, Masaki Otagiri

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Nanoparticles prepared using human serum albumin (HSA) have emerged as versatile carriers for improving the pharmacokinetic profile of drugs. The desolvation of HSA using ethanol followed by stabilization through crosslinking with glutaraldehyde is a common technique for preparing HSA nanoparticles, but our knowledge concerning the characteristics (or functions) of HSA nanoparticles and their efficiency when loaded with drugs is limited. To address this issue in more detail, we prepared anthracycline-loaded HSA nanoparticles. Doxorubicin-loaded HSA nanoparticles with a size similar to doxorubicin-unloaded particles could be prepared by desolvating at a higher pH (8-9), and the size (100-150 nm) was optimum for delivery to tumor tissues. Using this procedure, HSA nanoparticles were loaded with other anthracycline derivatives, and all showed cytotoxicity in cancer cells. However, the efficiency of drug loading and dissolution rate were different among them possibly due to the differences in the type of association of the drugs on nanoparticles (doxorubicin and daunorubicin; covalently bound to nanoparticles, pirarubicin; both covalently bound to and adsorbed on nanoparticles, aclarubicin; adsorbed on nanoparticles). Since the formulation of such drug-loaded HSA nanoparticles should be modified for efficient delivery to tumors, the findings reported herein provide the useful information for optimizing the formulation and the production process for the HSA nanoparticles using a desolvation technique.

Original languageEnglish
Pages (from-to)382-390
Number of pages9
JournalChemical and Pharmaceutical Bulletin
Volume66
Issue number4
DOIs
Publication statusPublished - 2018 Jan 1
Externally publishedYes

Fingerprint

Anthracyclines
Serum Albumin
Nanoparticles
Derivatives
Doxorubicin
Pharmaceutical Preparations
In Vitro Techniques
Tumors
Aclarubicin
Neoplasms
Drug Compounding
Daunorubicin
Pharmacokinetics
Glutaral
Cytotoxicity
Crosslinking
Dissolution
Ethanol
Stabilization
Cells

Keywords

  • Anthracycline derivative
  • Desolvation
  • Human serum albumin
  • Nanoparticle

ASJC Scopus subject areas

  • Chemistry(all)
  • Drug Discovery

Cite this

Preparation and in vitro analysis of human serum albumin nanoparticles loaded with anthracycline derivatives. / Kimura, Kotaro; Yamasaki, Keishi; Nakamura, Hideaki; Haratake, Mamoru; Taguchi, Kazuaki; Otagiri, Masaki.

In: Chemical and Pharmaceutical Bulletin, Vol. 66, No. 4, 01.01.2018, p. 382-390.

Research output: Contribution to journalArticle

Kimura, Kotaro ; Yamasaki, Keishi ; Nakamura, Hideaki ; Haratake, Mamoru ; Taguchi, Kazuaki ; Otagiri, Masaki. / Preparation and in vitro analysis of human serum albumin nanoparticles loaded with anthracycline derivatives. In: Chemical and Pharmaceutical Bulletin. 2018 ; Vol. 66, No. 4. pp. 382-390.
@article{233401f90cbb467588031b24b9591482,
title = "Preparation and in vitro analysis of human serum albumin nanoparticles loaded with anthracycline derivatives",
abstract = "Nanoparticles prepared using human serum albumin (HSA) have emerged as versatile carriers for improving the pharmacokinetic profile of drugs. The desolvation of HSA using ethanol followed by stabilization through crosslinking with glutaraldehyde is a common technique for preparing HSA nanoparticles, but our knowledge concerning the characteristics (or functions) of HSA nanoparticles and their efficiency when loaded with drugs is limited. To address this issue in more detail, we prepared anthracycline-loaded HSA nanoparticles. Doxorubicin-loaded HSA nanoparticles with a size similar to doxorubicin-unloaded particles could be prepared by desolvating at a higher pH (8-9), and the size (100-150 nm) was optimum for delivery to tumor tissues. Using this procedure, HSA nanoparticles were loaded with other anthracycline derivatives, and all showed cytotoxicity in cancer cells. However, the efficiency of drug loading and dissolution rate were different among them possibly due to the differences in the type of association of the drugs on nanoparticles (doxorubicin and daunorubicin; covalently bound to nanoparticles, pirarubicin; both covalently bound to and adsorbed on nanoparticles, aclarubicin; adsorbed on nanoparticles). Since the formulation of such drug-loaded HSA nanoparticles should be modified for efficient delivery to tumors, the findings reported herein provide the useful information for optimizing the formulation and the production process for the HSA nanoparticles using a desolvation technique.",
keywords = "Anthracycline derivative, Desolvation, Human serum albumin, Nanoparticle",
author = "Kotaro Kimura and Keishi Yamasaki and Hideaki Nakamura and Mamoru Haratake and Kazuaki Taguchi and Masaki Otagiri",
year = "2018",
month = "1",
day = "1",
doi = "10.1248/cpb.c17-00838",
language = "English",
volume = "66",
pages = "382--390",
journal = "Chemical and Pharmaceutical Bulletin",
issn = "0009-2363",
publisher = "Pharmaceutical Society of Japan",
number = "4",

}

TY - JOUR

T1 - Preparation and in vitro analysis of human serum albumin nanoparticles loaded with anthracycline derivatives

AU - Kimura, Kotaro

AU - Yamasaki, Keishi

AU - Nakamura, Hideaki

AU - Haratake, Mamoru

AU - Taguchi, Kazuaki

AU - Otagiri, Masaki

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Nanoparticles prepared using human serum albumin (HSA) have emerged as versatile carriers for improving the pharmacokinetic profile of drugs. The desolvation of HSA using ethanol followed by stabilization through crosslinking with glutaraldehyde is a common technique for preparing HSA nanoparticles, but our knowledge concerning the characteristics (or functions) of HSA nanoparticles and their efficiency when loaded with drugs is limited. To address this issue in more detail, we prepared anthracycline-loaded HSA nanoparticles. Doxorubicin-loaded HSA nanoparticles with a size similar to doxorubicin-unloaded particles could be prepared by desolvating at a higher pH (8-9), and the size (100-150 nm) was optimum for delivery to tumor tissues. Using this procedure, HSA nanoparticles were loaded with other anthracycline derivatives, and all showed cytotoxicity in cancer cells. However, the efficiency of drug loading and dissolution rate were different among them possibly due to the differences in the type of association of the drugs on nanoparticles (doxorubicin and daunorubicin; covalently bound to nanoparticles, pirarubicin; both covalently bound to and adsorbed on nanoparticles, aclarubicin; adsorbed on nanoparticles). Since the formulation of such drug-loaded HSA nanoparticles should be modified for efficient delivery to tumors, the findings reported herein provide the useful information for optimizing the formulation and the production process for the HSA nanoparticles using a desolvation technique.

AB - Nanoparticles prepared using human serum albumin (HSA) have emerged as versatile carriers for improving the pharmacokinetic profile of drugs. The desolvation of HSA using ethanol followed by stabilization through crosslinking with glutaraldehyde is a common technique for preparing HSA nanoparticles, but our knowledge concerning the characteristics (or functions) of HSA nanoparticles and their efficiency when loaded with drugs is limited. To address this issue in more detail, we prepared anthracycline-loaded HSA nanoparticles. Doxorubicin-loaded HSA nanoparticles with a size similar to doxorubicin-unloaded particles could be prepared by desolvating at a higher pH (8-9), and the size (100-150 nm) was optimum for delivery to tumor tissues. Using this procedure, HSA nanoparticles were loaded with other anthracycline derivatives, and all showed cytotoxicity in cancer cells. However, the efficiency of drug loading and dissolution rate were different among them possibly due to the differences in the type of association of the drugs on nanoparticles (doxorubicin and daunorubicin; covalently bound to nanoparticles, pirarubicin; both covalently bound to and adsorbed on nanoparticles, aclarubicin; adsorbed on nanoparticles). Since the formulation of such drug-loaded HSA nanoparticles should be modified for efficient delivery to tumors, the findings reported herein provide the useful information for optimizing the formulation and the production process for the HSA nanoparticles using a desolvation technique.

KW - Anthracycline derivative

KW - Desolvation

KW - Human serum albumin

KW - Nanoparticle

UR - http://www.scopus.com/inward/record.url?scp=85044834728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044834728&partnerID=8YFLogxK

U2 - 10.1248/cpb.c17-00838

DO - 10.1248/cpb.c17-00838

M3 - Article

VL - 66

SP - 382

EP - 390

JO - Chemical and Pharmaceutical Bulletin

JF - Chemical and Pharmaceutical Bulletin

SN - 0009-2363

IS - 4

ER -